How to sequence antibody–drug conjugates in metastatic breast cancer? Target switching alone may not be the answer
The first prospective phase II trials evaluating TOPO1 ADC after prior TOPO1 ADC therapy confirm the emergence of cross-resistance
Novel emerging targets, new treatment opportunities
Drug development in oncology is increasingly moving towards integrated strategies that consider tumour cells, their microenvironment and anatomical context
Overcoming resistance to immunotherapy in NSCLC?
Understanding the evolution of immunotherapy resistance holds the key to developing novel strategies in NSCLC
CTLA-4 targeting leads to improved overall survival in NSCLC progressing on immunotherapy
Early phase III trial results signal a much-needed chemotherapy-free advance with gotistobart in a setting where therapeutic choices are limited
Meta-analysis shows non-inferiority of later versus earlier immunotherapy administration in lung cancer
Chrono-immunotherapy may influence treatment outcomes, especially during the early phase of treatment, but its overall clinical impact remains to be clearly defined
From bispecific to multispecific antibodies: a highly promising field
Development of therapies modulating two or more targets is increasing rapidly despite facing a number of hurdles
Data show how ESMO’s scales and recommendations can guide the optimisation of outcomes in patients with targetable mutations
In two studies, the use of ESCAT matching and ESMO recommendations for germline assessment lead to effective targeted treatment
Data highlight the clinical feasibility of targeting the CD47-SIRPα axis mediating immunotherapy resistance
Early activity and manageable safety were demonstrated in two phase I trials with innovative agents
RAS inhibition: a game changer in pancreatic cancer?
The hope for innovative and effective RAS-inhibitors is high for this tumour type, but research in this area is challenging
Cancer Research
Rethinking the immunotherapy paradigm for a sustainable and equal cancer care
Dose optimisation of immune checkpoint inhibitors may help address current healthcare resource constraints and improve treatment access